EGFR and non-small cell lung carcinoma: Determining the mutational status of KRAS is essential before initiating treatment plans for cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), particularly when considering therapies targeting the epidermal growth factor receptor (EGFR) [18].